The worldwide increase in the prevalence of type 2 diabetes represents a tremendous challenge for our healthcare system, especially if we consider that this phenomenon is largely explained by the epidemic of obesity. However, despite the wellrecognized increased morbidity and mortality associated with an elevated body weight, there is now more and more evidence highlighting that abdominal adipose tissue is the fat depot that conveys the greatest risk of metabolic complications. This cluster of metabolic abnormalities has been referred to as the metabolic syndrome and this condition is largely the consequence of abdominal obesity, especially when accompanied by a high accumulation of visceral adipose tissue. This cluster of metabolic complications has also been found to be predictive of a substantially increased risk of coronary heart disease beyond the presence of traditional risk factors. Moreover, a moderate weight loss in initially abdominally obese patients is associated with a selective mobilization of visceral adipose tissue, leading to improvements in the metabolic risk profile predictive of a reduced risk of coronary heart disease and of type 2 diabetes. The recent discovery of the endocannabinoid-CB 1 receptor system and of its impact on the regulation of energy metabolism represents a significant advance, which will help physicians target abdominal obesity and its related metabolic complications. In this regard, studies have shown that rimonabant therapy (the first developed CB 1 blocker) could be useful for the management of clustering cardiovascular disease risk factors in high-risk abdominally obese patients through its effects not only on energy balance but also on adipose tissue metabolism. For instance, the presence of CB 1 receptors in adipose tissue and the recently reported effect of rimonabant on adiponectin production by adipose cells may represent a key factor responsible for the weight loss-independent effect of this CB 1 blocker on cardiometabolic risk variables.
The health hazards of obesity are well recognized. 1, 2 However, physicians have been constantly challenged by the relatively normal metabolic risk profile observed in some massively obese individuals. On the other hand, it is not uncommon in clinical practice to find individuals who are almost normal weight (from a body mass index standpoint) but with a cluster of atherogenic metabolic complications. How can we reconcile this substantial patient-to-patient variation with findings from epidemiological studies clearly showing that body mass index has a continuous relationship with complications such as type 2 diabetes and cardiovascular disease (CVD)? 1, 2 Over the last two decades, a whole series of imaging and metabolic studies have indicated that, in both genders, the amount of intra-abdominal or visceral adipose tissue measured by techniques such as computed tomography is an important correlate of a substantially disturbed metabolic risk factor profile predictive of an increased risk of type 2 diabetes and CVD. [3] [4] [5] [6] [7] [8] Thus, among equally overweight/obese subjects carefully matched for their level of total body fat, patients with a selective excess of visceral adipose tissue are at a substantially increased risk of showing the well-described abnormalities of insulin resistance, which are now commonly referred to as the metabolic syndrome. 4, [9] [10] [11] Therefore, although there is evidence that excess adiposity increases the risk of finding chronic complications in various populations of the world, there is compelling evidence that when assessing individual patients in clinical practice, viscerally obese individuals represent the subgroup of overweight/obese patients characterized by the most severe metabolic abnormalities.
guidelines 16 and more recently by the joint American Heart Association-National Heart, Lung, and Blood Institute (AHA-NHLBI) statement 17 that abdominal obesity is by far the most prevalent form of insulin resistance has been a remarkable advance, emphasizing the importance of measuring waist circumference in clinical practice as an initial step to identify patients likely to have abdominal obesity. However, despite being very helpful to clinicians, these guidelines have fuelled a debate around whether insulin resistance or abdominal obesity is the key core culprit for the whole set of metabolic abnormalities found in individuals with insulin resistance. 18, 19 The present paper endorses the thesis that insulin resistance is a central mechanism associated with atherogenic and diabetogenic features that are now referred to as the metabolic syndrome. However, in clinical practice, it should be emphasized that the form of insulin resistance which is by far the most prevalent is observed in patients with an elevated waist circumference and with the abnormalities of the metabolic syndrome. These abnormalities can be identified by the presence of simple clinical variables such as elevated triglycerides, low high-density lipoprotein (HDL)-cholesterol, elevated glycemia and hypertension. 20 Among these screening tools, there is compelling data suggesting that the presence of an elevated waist circumference combined with hypertriglyceridemia is sufficient to identify a large proportion of patients meeting the NCEP-ATP III criteria for the metabolic syndrome.
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The dyslipidemia of abdominal obesity: beyond LDL-cholesterol
It is important to point out that plasma low-density lipoprotein (LDL)-cholesterol concentration is not increased in abdominally obese patients with excess visceral adipose tissue. 5, 9 However, the clinician should not be misled by such apparently normal LDL-cholesterol levels. The dyslipidemia of visceral obesity has been extensively studied and reported to include hypertriglyceridemia, increased apolipoprotein B levels, reduced HDL-cholesterol concentrations, an elevated cholesterol/HDL-cholesterol ratio and an increased proportion of small LDL and HDL particles. This dyslipidemic state is also found in patients meeting the clinical criteria of the metabolic syndrome. The review of the mechanism(s) linking visceral obesity to insulin resistance and to the above atherogenic dyslipidemic state has been the topic of several previous papers, 1, 8, 14, 32 and their discussion is beyond the scope of the present paper.
Adipose tissue: an endocrine organ?
In addition to its well-established role in lipid storage and mobilization, adipose tissue is a remarkable endocrine organ that produces prothrombotic and inflammatory molecules. 33, 34 These 'adipokines' could also contribute to increase the patient's risk of diabetes and coronary heart disease (CHD). For instance, viscerally obese patients have an impaired fibrinolysis and elevated concentrations of thrombotic markers. [35] [36] [37] [38] [39] [40] Markedly elevated plasma C-reactive protein (CRP) concentrations have been reported in abdominally obese patients, the highest levels being found in obese patients with a selective excess of visceral adipose tissue, suggesting the presence of an inflammatory profile. 6 Elevated CRP levels may be resulting from the effects of elevated interleukin-6 (IL-6) and tumor necrosis factor-a originating from the expanded abdominal adipose tissue. 34, 41, 42 Recently, another adipose tissue-specific cytokine, adiponectin, has been reported to be reduced in abdominally obese patients with high levels of visceral adipose tissue. 43, 44 Low adiponectin concentrations could contribute to insulin resistance and CHD. 45, 46 For instance, low adiponectin levels have been found in both type 2 diabetic patients and in patients with documented CHD. 45, 47 Some evidence is also available, which suggests that a low adiponectin concentration may be predictive of an increased CHD risk even after control for conventional CHD risk factors. 48 Adiponectin has several metabolic properties in vitro, which are compatible with its apparently protective effects against type 2 diabetes and CHD. [49] [50] [51] Among those, the effects of adiponectin on insulin sensitivity and on metabolic processes controlling HDLcholesterol levels are well documented. 52, 53 For instance, an independent association between plasma adiponectin and HDL-cholesterol has been reported. 44, 53 We have also shown that the lowest plasma HDL-cholesterol concentrations were found in men with both excess visceral adiposity and low adiponectin levels. 44 The low adiponectin concentration found in viscerally obese patients could therefore be one of the key mediators of the insulin-resistant, atherogenic metabolic profile observed in these patients (Figure 1a ). On the basis of these results, it may be relevant, from a therapeutic standpoint, to consider pharmacological approaches, which would induce both a mobilization of visceral adipose tissue and a stimulation of adiponectin production by fat cells (Figure 1b) . The above evidence suggests that viscerally obese patients, even in the absence of classical CVD risk factors (hypertension, hyperglycemia, elevated LDL-cholesterol concentrations), could be at increased risk of CHD owing to the presence of an atherogenic, prothrombotic and inflammatory profile. [12] [13] [14] [15] However, although several features of this metabolic syndrome have been shown to predict an increased CHD risk, which features of the metabolic syndrome are critical to assess in order to improve our ability to predict CHD events once traditional risk factors are taken into account remains an unresolved question for which there is uncertainty and debate.
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Features of the metabolic syndrome in abdominal obesity vs CHD risk
There is evidence that features of the metabolic syndrome found in abdominally obese men increase CHD risk, even in the absence of type 2 diabetes. [55] [56] [57] Prospective studies have
shown that fasting hyperinsulinemia, a crude marker of insulin resistance in nondiabetic individuals, predicted an increased CHD risk. [58] [59] [60] [61] In the Québec Cardiovascular Study, it was reported that some of the metabolic features of abdominal obesity, namely fasting hyperinsulinemia, elevated apolipoprotein B concentration, increased proportion of small LDL particles, an increased cholesterol/HDL-cholesterol ratio, and elevated IL-6 and CRP concentrations (markers of low chronic inflammation) were all predictive of an increased risk of CHD. 58, [62] [63] [64] [65] [66] Most of these markers are not, however, well-accepted CHD risk factors in current medical practice. We have therefore quantified, in middle aged men of the Québec Cardiovascular Study, the ability of some of these markers (the atherogenic metabolic triad of elevated insulin and apolipoprotein B levels and small LDL particles) to predict CHD risk compared to commonly used algorithms based on classical risk factors such as the Framingham risk chart. 67 As expected, we found that a high
Framingham score was predictive of an increased risk of CHD. However, among men with a low Framingham score (owing to the absence of traditional risk factors), we nevertheless observed that the features of the metabolic syndrome were predictive of an increased risk of CHD. 67 These results are of significance in the context of the current debate 18, 54 as to the usefulness in clinical practice of considering the features of the metabolic syndrome in global risk assessment. For instance, although we are providing evidence that some markers of the metabolic syndrome add to global risk assessed by algorithms such Framingham, this finding will have to be confirmed in other prospective studies and in various populations of the world. The issue of whether or not the metabolic markers add to overall global risk once traditional and treatable risk factors are evaluated is of critical importance in order to recommend (or not) the assessment and interpretation of additional metabolic markers to improve global risk assessment in clinical practice. As mentioned above, we need to keep in mind that there is evidence that our current risk assessment algorithm based on Framingham risk factors does not always identify high-risk individuals with the features of the metabolic syndrome when these individuals do not have traditional risk factors such as hypertension, smoking, elevated LDLcholesterol or type 2 diabetes. There is therefore a need to further refine current CHD risk assessment algorithms by incorporating critical markers of the metabolic syndrome. Which combination of markers would provide the optimal discrimination of high-risk individuals at the lowest possible cost while being easily standardized remains a daunting task, which will require a considerable amount of work. In this regard, the development of the 'hypertriglyceridemic waist' concept 27 was an attempt to develop a simple screening approach, which could help primary-care physicians identify, at low cost, the subgroup of abdominally obese patients with the atherogenic features of the metabolic Figure 1 (a) Weight loss in initially viscerally obese patients has been associated with a preferential loss of visceral adipose tissue measured by computed tomography. It is proposed that the substantial reduction in waist circumference produced by rimonabant therapy is likely to be accompanied by a substantial loss of visceral adipose tissue, which will have to be quantified in future studies. (b) It is well established that a loss of visceral adipose tissue mass is associated with improvements in the cardiometabolic risk profile. Furthermore, there is evidence that the increased adiponectin production produced by rimonabant therapy partly explains the weight-loss-independent effect on metabolic risk variables. Additional studies that will dissect out the respective effects of rimonabant on metabolic parameters mediated by the loss of visceral adipose tissue vs the increased adiponectin levels are clearly warranted. Targeting abdominal obesity among patients with the metabolic syndrome
Although there is substantial evidence that viscerally obese patients represent the subgroup of obese subjects at highest risk of type 2 diabetes and CHD, no intervention study has provided evidence yet that a selective loss of visceral adipose tissue would be predictive of metabolic improvements reducing the incidence of type 2 diabetes and CHD. In this regard, data from two landmark intervention trials performed among subjects with impaired glucose tolerance who were largely abdominally obese have provided convincing support to the notion that moderate weight loss is associated with a substantial reduction (of almost 60%) in the probability of converting from an impaired glucose tolerance state to type 2 diabetes. 72, 73 However, one could question why such a moderate weight loss of only a few percents of initial body weight could produce such tremendous clinical benefits. There is evidence that if we induce moderate weight lost in initially viscerally obese patients, we should expect a selective mobilization of visceral adipose tissue. [74] [75] [76] For instance, a 5-10% weight loss could induce a mobilization of visceral fat, which may reach 30-40% depending upon the patient's initial profile. [74] [75] [76] Therefore, such selective mobilization of visceral fat could have a profound and favorable effect on the cardiometabolic risk profile of viscerally obese patients. 13 Although this hypothesis is appealing, it should be emphasized that it has never been tested in a large randomized trial with hard end points. Such studies are very much needed.
Management of abdominal obesity by targeting the endocannabinoid system with CB 1 blockade
The recent discovery of the endocannabinoid-CB 1 receptor system (EC system) 77 and of its impact on the regulation of energy metabolism 78 represents a significant advance which has paved the way to the development of new pharmacological approaches which could fill an unmet clinical need: targeting abdominal obesity and its related metabolic complications. The EC system includes a family of locally produced endogenous agonists that are phospholipid derivatives (endocannabinoids) 79, 80 and the G I/O -protein-coupled CB 1 receptor, 81 which they activate. These CB 1 receptors have been located in key areas of the brain involved in the regulation of appetite/satiety as well as in several tissues/ organs such as the autonomic nervous system, the liver, skeletal muscle, gastrointestinal tract and adipose tissue. 77, 82 Endocannabinoids are produced on demand postsynaptically and degraded rapidly. Anandamide was the first endocannabinoid to be discovered, followed then by 2-arachidonoyl-glycerol (2-AG). 79, 83 The administration of endocannabinoids in animals has been shown to increase energy intake, even in satiated rodents. 83, 84 Such a stimulating effect of endocannabinoids on food intake are not observed in CB 1 receptor knockout animals, indicating that the effect of anandamide and 2-AG are mediated by CB 1 receptors. Furthermore, CB 1 knockout mice have a lean body composition phenotype and they are resistant to dietinduced obesity compared to wild-type animals. 78 There is therefore considerable evidence supporting the notion that the EC system has an important role in the regulation of energy balance. 85 On that basis, blocking the CB 1 receptor could represent an interesting approach for the management of high-risk abdominal obesity and related cardiometabolic risk. Evidence derived from recently completed phase III trials in overweight/obese patients suggests that such an approach may yield substantial clinical benefits.
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Metabolic effects of targeting the EC system by CB 1 blockade: evidence of a weight loss-independent effect
Reviews of animal studies which have targeted the EC system with the first developed CB 1 blocker rimonabant have indicated that this drug could induce a reduction in food intake, loss of body weight and body fat, and could improve insulin sensitivity and blood lipids. 77, 82 However, pair feeding experiments have suggested that rimonabant could favorably alter the metabolic profile beyond what could be explained by weight loss. 78 To explain that putative weightindependent effect of the drug, an exciting development has been the discovery of the presence of CB 1 receptors on other tissues and organs among which there is adipose tissue. 78, 88 Indeed, the stimulation of CB 1 receptors in fat cells has been shown to promote lipogenesis, 78 which would lead to fat cell hypertrophy and to a reduced production of adiponectin by enlarged adipose cells. Such results obtained in animal studies are compatible with the concept that an overstimulation of the EC system in human abdominal obesity would lead to fat cell hypertrophy and to markedly reduced plasma adiponectin levels, which are well-described features of abdominal obesity. 44 Furthermore, we have recently reported that the low plasma adiponectin concentration observed in viscerally obese patients was a key factor responsible for their markedly reduced HDL-cholesterol levels. 44 For instance, both the amount of visceral fat and plasma adiponectin levels were found to be independent predictors of plasma HDL-cholesterol levels. Thus, stimulation of fat cell CB 1 receptors resulting from an overproduction of endocannabinoids would lead to fat cell hypertrophy, low plasma adiponectin concentrations and reduced plasma HDL-cholesterol levels. Furthermore, as adiponectin has a well-documented effect on insulin signalling and insulin sensitivity, 52 such a link could represent the mechanisms by which the overstimulated EC system of abdominally obese patients leads to the development of insulin resistance through hypoadiponectinemia. Very recently, Osei-Hyiaman et al. 89 have also provided evidence of a very significant effect of endocannabinoids on liver lipogenesis. Under this model, an overactivated EC system would also contribute to fat accumulation in the liver, leading to related metabolic impairments, and eventually to liver steatosis, the latter being another well-described feature of viscerally obese patients. [90] [91] [92] Thus, CB 1 blockade with rimonabant undoubtedly reduces food intake leading to weight loss and to related metabolic improvements, but a weight-loss-independent effect of this drug should also be expected from its mechanism of action, likely to be mediated by the blockade of CB 1 receptors located in key systemic metabolic organs/ tissues such as the liver and adipose tissue (Figure 2 ). Rimonabant is currently the first CB 1 receptor blocker under clinical development. It has been shown to reduce food intake and body weight in treated animals and to alter Under this model, CB 1 blockade in key areas of the hypothalamus involved in the regulation of energy balance produces a reduction in food intake leading to weight loss. However, as CB 1 receptors are also expressed in the gut, liver, skeletal muscle and adipose tissue, CB 1 blockade may lead to metabolic improvements, which could also be partly independent from the reduced food intake and related weight loss. Current evidence is particularly compelling for the effects of CB 1 blockade on liver lipogenesis (decreased) as well as on adiponectin production by fat cells (increased). These tissue-specific effects are compatible with the reported beneficial effects of rimonabant on the plasma lipoprotein profile and on plasma glucose-insulin homeostasis, such improvements being partly explained by the concomitant increase in plasma adiponectin levels. As abdominally obese individuals with excess visceral adipose tissue have low plasma adiponectin levels, it is suggested that these patients would particularly benefit from a pharmacological approach targeted at the endocannabinoid system. adipose tissue metabolic activity 93 while inducing the expression of the adiponectin gene. 94 Two phase III studies with rimonabant have been recently reported in peerreviewed publications. 86, 87 The key effects of rimonabant on anthropometric, metabolic and CVD risk variables reported in completed phase III studies are summarized in Table 1 . The first published trial (RIO-Europe) had revealed that rimonabant treatment for 1 year induced significant weight loss, produced a substantial reduction in waist circumference while improving metabolic risk factors for diabetes and CVD in patients with overall obesity. 86 For instance, treatment with rimonabant at 20 mg/day was shown to substantially increase HDL-cholesterol concentration and to reduce plasma triglyceride levels, whereas reducing fasting insulin levels as well as the 2-h plasma insulin levels measured during an oral glucose load. Regression analyses of changes in body weight over changes in metabolic parameters in the placebo and in the rimonabant (20 mg/day) arm revealed that about 50% of these metabolic effects were found to be independent from the change in body weight, a finding compatible with the systemic metabolic effects of rimonabant on CB 1 receptors also located on liver and fat cells. Another 1-year study, this time specifically designed to test the effect of rimonabant in dyslipidemic overweight/obese patients (RIO-Lipids) also reported that rimonabant therapy (20 mg/day) led to a significant decrease in body weight as well as to a substantial mobilization of abdominal adipose tissue as indicated by a considerable reduction in waist circumference. 87 Such loss of abdominal fat was accompanied by significant improvements in metabolic parameters such as glucose tolerance, reduction in plasma insulin levels (fasting and during a 75 g oral glucose tolerance test), reduction in triglyceride concentrations and increased in HDL-cholesterol levels. Furthermore, the prevalence of patients meeting the NCEP-ATP III criteria for the metabolic syndrome was reduced by about one-half among patients treated with rimonabant (20 mg/day). Additional analyses in the RIO-Lipids study revealed that patients treated with rimonabant (20 mg/day) showed additional improvements in other cardiometabolic risk markers such as an increase in LDL particle size as well as decreases in the proportion of atherogenic small LDL particles and in CRP concentrations, the latter variable being currently considered as an important marker of inflammation-related CHD risk. 95 As mentioned above, abdominal obesity is a condition associated with reduced plasma adiponectin concentrations, such low adiponectin levels being partly responsible for the diabetogenic and atherogenic metabolic risk profile observed among abdominally obese patients with excess levels of intraabdominal adipose tissue. Additional analyses conducted among RIO-Lipids patients at baseline revealed that a low adiponectin concentration was associated with evidence of insulin resistance, inflammation and with an atherogenic dyslipidemia. 96 Rimonabant 20 mg/day treatment increased plasma adiponectin levels by 57% and to a significantly greater extent than in the placebo group. Furthermore, such an increase in adiponectin levels produced by rimonabant was found to be greater than what could be explained by the concomitant weight loss. 87 Significant positive correlations were found between changes in adiponectin levels produced by rimonabant therapy and changes in HDL-cholesterol levels. Taken together, these results support the notion that both the loss of abdominal fat and the specific effect of rimonabant on adiponectin levels are among the important factors explaining the effect of this CB 1 blocker on metabolic risk factors for type 2 diabetes and CVD. Thus, rimonabant therapy could be useful for the management of clustering CVD risk factors in high-risk abdominally obese patients through its marked effects on both abdominal adiposity and related metabolic risk factors. In summary, there is solid evidence that the most prevalent form of the metabolic syndrome is associated with abdominal obesity, especially when accompanied by a selective deposition of visceral adipose tissue. This notion has important clinical implications as it does recognize the importance of identifying the expanded waist girth of metabolic syndrome patients as a therapeutic target for the optimal management of their elevated CHD risk. Although most physicians have heard about the metabolic syndrome and now recognize its importance, they are nevertheless confused on how to detect patients with the metabolic syndrome, how to optimally assess their CHD risk and how to manage them, with proper identification of key variables and targets. For instance, many physicians are confusing pathophysiology and clinical screening tools. 97 Although a considerable amount of additional research will be needed to fully understand which features of the metabolic syndrome are the key variables modulating CHD risk, simple and discriminant tools will have to be provided to clinicians as there is an urgent need to implement efficient screening strategies to identify high-risk abdominally obese patients. It is proposed that while we await the results of sophisticated prospective observational studies and of randomized trials that will untangle the key metabolic markers of the metabolic syndrome driving CHD risk beyond the contribution of classical risk factors, the simultaneous presence in clinical practice of abdominal obesity (increased waist) and of hypertriglyceridemia may help in the identification of a large number of abdominally obese patients with the features of the metabolic syndrome. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Finally, despite the remarkable progress made in our ability to treat CVD risk factors by pharmacotherapy, our clinical efficacy is limited and the majority of high-risk treated patients remain at elevated global risk for an acute coronary event. Until abdominal obesity is identified as a key therapeutic target, it is proposed that we will not optimally manage the risk of CVD in a large proportion of high-risk patients. 13 In this regard, recent results available from clinical trials completed with rimonabant 86,87 provide convincing evidence that CB 1 blockade may represent a relevant and promising approach to target an unmet clinical need: the management of high-risk abdominal obesity. Let us just hope that this promising drug will never end up in the hands of individuals who would like to 'sell' weight loss for cosmetic purposes rather than for health.
